Expressions of tissue factor and vascular endothelial growth factor in diffuse large B-cell lymphoma and their clinical significances / 白血病·淋巴瘤

Objective@#To investigate the expressions of tissue factor (TF) and vascular endothelial growth factor (VEGF) in diffuse large B-cell lymphoma (DLBCL) and their clinical significances.@*Methods@#The clinical data of 80 cases of DLBCL diagnosed at the Second People's Hospital of Lianyungang from January 2010 to December 2017 were collected, and 30 cases of reactive hyperplasia of lymph node (RLN) were selected as the controls. The expressions of TF and VEGF in the two groups were detected by using immunohistochemical staining.@*Results@#The positive rate of TF and VEGF in the DLBCL group was higher than that in the RLN group [TF: 86.3% (69/80) vs. 50.0% (15/30) ; VEGF: 90.0% (72/80) vs. 53.3% (16/30) ; both P < 0.01]. And there was a positive correlation between the expression of TF and VEGF (r = 0.704, P < 0.05). There was no significant difference in the positive rates of TF and VEGF among the patients with different gender, age and Hans subtypes in DLBCL group (all P > 0.05). The positive rate of TF in DLBCL patients with B symptom, increased LDH, physical status grade ≥2, and extranodal lesion number >1 was higher (all P < 0.05). The positive rate of VEGF in patients with Ann Arbor stage Ⅲ-Ⅳ, B symptom, increased LDH, and extranodal lesion number >1 was higher (all P < 0.05). The positive rate of TF in international prognostic index (IPI) high-risk group was higher than that in low-risk group (P < 0.01); the positive rate of VEGF in IPI high-risk group and middle-high-risk group was higher than that in low-risk group (all P < 0.01). The expressions of TF (r = 0.491, P < 0.01) and VEGF (r = 0.529, P < 0.01) were positively correlated with IPI. The overall survival rates of TF and VEGF low-expression group were higher than those of TF and VEGF high-expression group (both P < 0.05).@*Conclusion@#The expressions of TF and VEGF are highly expressed in DLBCL, which is associated with the IPI. It can provide a reference value in evaluating prognosis of DLBCL.

Relationship Between Dual Time Point FDG PET/CTand Clinical Prognostic Indexes in Patients with High Grade Lymphoma: a Pilot Study / 대한핵의학회잡지

PURPOSE: This study investigated the correlative relationship between metabolic parameters estimated from dual time point 2-deoxy-2-[¹⁸F] fluoro-D-glucose (¹⁸F-FDG) positron emission tomography/computerized tomography (PET/CT) and the clinical tools predicting the outcome of a lymphoma. We also measured metabolic and volumetric alterations between early and delayed ¹⁸F-FDG PET/CT in patients with high grade lymphoma (HGL).METHODS: The samples were 122 lymph nodes and extralymphatic lesions from 26 patients diagnosed with HGL. All patients were applied to the International Prognostic Index (IPI), Ann Arbor stage, and revised IPI as clinical prognostic parameters. ¹⁸F-FDG dual time point PET/ CT (DTPFP) consisted of an early scan 1 h after ¹⁸F-FDG injection and a delayed scan 2 h after the early scan. Based on an analysis of DTPFP, we estimated the standardized uptake value (SUV) of tumors from the early and delayed scans, retention index (RI) representing the percentage change between early and delayed SUV, and metabolic volume different index (MVDI) calculated using metabolic tumor volumes (MTV).RESULTS: RI(max) showed a multiple positive correlative relationship with stage and IPI in lesion-by-lesion analysis (p < 0.01). In the case of IPI, the high risk group exhibited higher RI(max) than the low risk group (p = 0.004). In the case of revised IPI, the RI(max) of the low risk group were significantly lower than the intermediate and high risk groups, respectively (p < 0.01). The MVDIs of the best outcome group were decreased in comparison to the moderate outcome group (p = 0.029). There was a significant negative correlative relationship between RI(max) and MVDI, and the inclinations for decreased MVDIs were slightly associated with increased RIs.CONCLUSIONS: RI(max) extracted from DTPFP had a significant relationship to extranodal involvement, staging, IPI, and revised IPI. MVDI showed significant negative correlation with RI(max). Further large scale studies are warranted to support and extend these preliminary results.

Prognostic significance of NCCN-International Prognostic Index (NCCN-IPI) for patients with peripheral T-cell lymphoma treated with CHOP-based chemotherapy / 中华血液学杂志

Objective@#To validate the prognostic value of NCCN-International Prognostic Index (NCCN-IPI) for patients with peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy.@*Methods@#A retrospective analysis in 162 PTCL patients who were initially diagnosed and treated in Rui Jin Hospital from January 2003 to May 2013 was conducted. Baseline characteristics were collected, and survival analysis was performed according to the IPI and NCCN-IPI model.@*Results@#The estimated 5-year overall survival (OS) rate and progression free survival (PFS) rate were 33% and 20%, with median OS and PFS of 17.0 months and 9.2 months, respectively. Multivariate analysis indicated ECOG score (PFS: HR=2.418, 95%CI 1.535-3.809, P<0.001; OS: HR=2.347, 95%CI 1.435-3.839, P= 0.001) , specific extra-nodal sites (PFS: HR=1.800, 95%CI 1.216-2.665, P=0.003; OS: HR=1.608, 95% CI 1.054-2.454, P=0.027) and pathology type (PFS: HR=0.424, 95% CI 0.184-0.975, P=0.043; OS: HR=0.276, 95% CI 0.087-0.877, P=0.029) were independent prognostic factors of OS and PFS for the patients with PTCL. The survival rates of low risk patients based on NCCI-IPI were remarkably higher than the counterparts based on IPI (5-year OS 74% vs 54%, χ2=5.041, P=0.025, 5-year PFS 50% vs 38%, χ2= 5.295, P=0.021) . NCCN-IPI was outstanding to identify the subgroup of low risk patients with PTCL, who may benefit from conventional chemotherapy such as CHOP or CHOP-like regimen.@*Conclusion@#NCCN-IPI is more powerful for low risk PTCL patients and a strong supplement for IPI.

Correlation of serum β2-microglobulin expression with the clinical characteristics and prognosis of mantle-cell lymphoma / 肿瘤

Objective: To investigate the correlation of serum β2-microglobulin (β2-MG) with overall survival and mantle-cell lymphoma international prognostic index (MIPI) of patients with mantle-cell lymphoma (MCL). Methods: The clinical data of 61 MCL patients admitted in Tianjin Medical University Cancer Institute and Hospital were retrospectively analyzed. Fisher's exact test was used to analyze the relationship between serum β2-MG level and the clinical features of MCL patients. COX proportional hazards model was used to analyze the influencing factors of prognosis in MCL patients. Results: In total of 61 MCL patients, 35 (57.4%) had abnormal elevation of serum β2-MG. The level of serum β2-MG was significantly associated with clinical stage (P = 0.011), B symptom (P = 0.032), bone marrow (P 2.5 mg/L have a poor overall survival as compared with the pateints with serum β2-MG ≤2.5 mg/L.

The prognostic signiifcance of peripheral blood ALC/AMC in follicular lymphoma patients treated with R-CHOP-like chemotherapy / 中国癌症杂志

Background and purpose:The prognostic capability of traditional prognostic index like follicular lymphoma international prognostic index (FLIPI) is limited in the rituximab era. This study was to investigate the prognostic significance of peripheral blood absolute lymphocyte count/absolute monocyte count (ALC/AMC) in Chinese patients with follicular lymphoma (FL).Methods:This study retrospectively analyzed 136 newly diagnosed FL patients who received rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP)-like chemotherapy in Department of Hematology, Ruijin Hospital from Jan. 2003 to Dec. 2013, and further classified these patients according to FLIPI scoring system.Results:According to FLIPI, 61 patients (44.9%) were stratified into the low-risk (0-1 points) group, 42 cases (30.9%) into the intermediate-risk (2 points) group, and 33 cases (24.2%) into the high-risk (3-5 points) group. The overall response rate and 2-year progression-free survival (PFS) of the 3 risk groups were 88.5%, 95.2%, and 78.8% (P=0.090), and 91.4%, 74.6%, and 47.8% (log-rank=23.3,P<0.001), respectively. The overall response rate and 2-year PFS for patients with ALC/AMC≥4.7 and <4.7 were 91.9%, 68.6% (P=0.005) and 96.0%, 69.7% (log-rank=13.0,P<0.001), respectively. In the multivariate study, ALC/AMC≥4.7 was independent of FLIPI and was able to distinguish the FLIPI low-risk and intermediate-risk patients (log-rank=7.535,P=0.006).Conclusion:For FL patients treated with R-CHOP-like regimens, ALC/AMC is a simple and effective biomarker reflecting tumor microenvironment and human immunity, and could be considered for prognosis evaluation.

Linfomas asociados a infección por VIH en pacientes del Hospital Clínico San Borja Arriarán / Fundación Arriarán2001-2008 / Lymphomas associated with HIV infection in patients at the Hospital San Borja Arriarán /Fundación Arriarán 2001-2008, Santiago, Chile

Introduction: Hodgkin lymphomas (HL) and non Hodgkin lymphomas (NHL) are frequently associated to acquired immunodeficiency syndrome in adults. Objective: To systematize the clinical features and histological characteristics of lymphomas in AIDS patients, its treatment and outcomes in our institution. Patients and Methods: Retrospective analysis of patients with HIV-associated lymphoma between January 2001 and December 2008 at the San Borja Arriarán Hospital complex. Results: Information was obtained from 30 patients with NHL and 7 with HL, with a median of 40 years. The majority of tumors were Burkitt lymphoma (47%), diffuse large cell lymphoma B-cell (37%) and NHL of T lineage (10%). There was no CNS or cavities lymphoma. Almost all patients (86.7%) with NHL were treated with CHOP chemotherapy, 57% of those receiving treatment had progression or relapse from complete remission. A rescue chemotherapy was indicated in 4 patients. 73% of patients receiving CHOP, complete 5 to 6 cycles of chemotherapy. The use of CHOP chemotherapy for the subgroup of patients with Burkitt lymphoma achieved low rates of complete remission and frequent relapse and disease progression, showing that CHOP was ineffective in improving survival, especially in high risk patients. We found statistically significant differences in survival according to IPIae (International prognostic Index age-adjusted). Conclusion: Non-Hodgkin lymphoma in HIV patients treated with chemotherapy protocols PAlNDA persists in our environment as a disease with a poor prognosis compared with findings in the international literature. The incorporation of new drugs of proven utility as rituximab and specific schemes chemotherapy could improve these results. The establishment of prognostic groups established by IPIae can guide clinical work for the use of chemotherapy tailored to their specific risk and optimized according to histological type.

Introducción: Los linfomas de Hodgkin (LH) y no Hodgkin (LNH) se asocian con alta frecuencia al síndrome de inmunodeficiencia humana en adultos. Objetivo: Sistematizar los aspectos clínicos e histológicos de los linfoma que afectan a pacientes con SIDA, su tratamiento y resultados globales en nuestra institución. Pacientes y Métodos: Análisis retrospectivo de pacientes con linfoma asociado a VIH entre enero de 2001 y diciembre de 2008 en el complejo hospitalario San Borja Arriarán. Resultados: Se obtuvo información de 30 pacientes con LNH y 7 LH, con una mediana de 40 años. Los tipos histológicos predominantes fueron linfoma de Burkitt (47 %), linfoma difuso de células grandes de estirpe B (37 %) y LNH de estirpe T (10%). No se diagnosticaron LNH del SNC ni linfoma de cavidades. Casi la totalidad de los pacientes (86,7%) con LNH se trataron con esquema CHOP, 57% de quienes recibieron tratamiento presentaron progresión o recaída desde remisión completa, ofreciéndoles una quimioterapia de rescate a cuatro pacientes. El 73% de los pacientes que recibieron CHOP lograron completar entre cinco y seis ciclos de quimioterapia. El uso de quimioterapia CHOP para el subgrupo de pacientes con linfoma de Burkitt alcanzó bajos porcentajes de remisión completa y mayoritariamente progresó la enfermedad, siendo esta quimioterapia, inefectiva para mejorar la sobrevida, especialmente en los pacientes de riesgo alto. Se encontraron diferencias estadísticamente significativas en sobrevida según el IPIae (índice internacional pronóstico ajustado por edad) al ingreso. Conclusión: El LNH en los pacientes con VIH tratados con los protocolos de quimioterapia PANDA persiste en nuestro medio como una enfermedad de muy mal pronóstico comparado con los resultados en la literatura internacional. La incorporación de nuevos fármacos de demostrada utilidad como rituximab y esquemas específicos de quimioterapia podrían mejorar estos resultados. El establecimiento de grupos pronósticos establecidos por IPIae puede orientar el trabajo clínico para el uso de quimioterapia ajustada a su riesgo específico y optimizado según tipo histológico.

Prognostic significance of follicular lymphoma international prognostic index (FLIPI) and FLIPI2 in follicular lymphoma patients treated with rituximab plus chemotherapy / 白血病·淋巴瘤

Objective To investigate the prognostic significance of follicular lymphoma international prognostic index (FLIPI) and FLIPI2 in Chinese FL patients for better prognostic model.Methods 63 newly diagnosed FL patients who received rituximab plus CHOP (cyclophosphamide,doxorubicin,vincristine and prednisone)-like chemotherapy from January 2003 to December 2010 were retrospectively analyzed according to FLIPI and FLIPI2 scoring system.Results According to FLIPI,31 patients (49.2 ％) were stratified into the low risk group (0-1 point),24 (38.1％) into the intermediate risk group (2 points),and 8 (12.7 ％) into the high risk group (3-5 points).As for FLIPI2 scoring,17 cases (27.0 ％) were classified in low risk group (0 point),42 cases (68.3 ％) in intermediate risk group (1-2 points),and 4 cases in high risk group (3-5 points).The overall response rates and 2-year progression free survival (PFS) rates of the three risk groups were 93.5 ％ (29/31),91.7 ％ (22/24),75.0 ％ (6/8) (P =0.27),and 85.7 ％,75.2 ％,58.8 ％ (Log-rank =1.063,P =0.59) respectively in FLIPI.In terms of FLIPI2,the overall response rates and 2-year PFS rates of the three groups were 100.0 ％ (17/17),90.7 ％ (39/42),50.0 ％ (2/4) (P =0.01) and 92.9 ％,74.0 ％,33.3 ％ (Log-rank =7.075,P =0.03).Conclusion FLIPI2 presents more robust prognostic significance than FLIPI in disease progression perspective for FL patients treated with R-CHOP like regimens in this study.

Relationship between the serum level of β2-microglobin and international prognostic index and the prognostic analysis of patients with peripheral T-cell lymphoma / 白血病·淋巴瘤

Objective To determine the relationship between the serum level of β2-microglobin (β2-MG)and international prognostic index (IPI) and investigate the role of IPI in predicting the prognosis and making individualized therapy for peripheral T-cell lymphoma (PTCL).Methods Eighty-one patients with PTCL were treated by standard CHOP regimen.The clinical characteristics,response,long-term surival rates and the relationship between serum level of β2-MG and IPI scores were analyzed retrospectively.Results Eighty-one patients were eligible.All of them were treated by CHOP regimen.The overall response rate (RR) was 82.7 ％ with 53.1％ complete remission (CR) rate.The RR of IPI low risk,low-intermediate risk,high-intermediate risk,and high risk were 95.7 ％,87.5 ％,53.8 ％ and 20.0 ％,with CR rate 74.5 ％,37.5 ％,15.4 ％ and 0,respectively (P ＜0.05).The median survival times (MST) were 31.2 months at a median follow-up of 30 months (2-98 months).The acturial 1-,3-,and 5-year overall survival (OS) rates were 83.5 ％,41.8 ％ and 34.7 ％,respectively.The 5-year OS rates of low risk,low-intermediate risk,high-intermediate risk,high risk were 57.3 ％,55.9 ％,0 and 0,respectively (P ＜0.05).The OS rates of low risk group (IPI 0-2 scores) and high risk group (IPI 3-5 scores) were 54.8 ％ and 0,respectively (P ＜0.05).Serum levels of β2-MG were significantly elevated in the high risk group than those in the low risk group.The proportion of abnormal serum level of [β2-MG were also significantly elevated in the high risk group than those in the low risk group.The results of multivariante analysis showed that serum level of β2-MG and IPI scores were independent prognostic factors for PTCL (P＜0.05).Conclusion The serum level of β2-MG with IPI scores system can be uscd for evaluating the prognosis of PTCL patients.

Clinical Relevance of Elevated Levels of Serum Soluble Interleukin-2 Receptor alpha (sIL-2Ralpha) in Patients with Non-Hodgkin's Lymphoma / 대한진단검사의학회지

Levels of soluble interleukin-2 receptor alpha (sIL-2Ralpha) are known to increase in the sera of patients with certain malignancies, including malignant lymphoma. This study aimed to assess the clinical significance of the sIL-2Ralpha level in non-Hodgkin's lymphoma (NHL). We used ELISA to measure the sIL-2Ralpha levels in 48 newly diagnosed and untreated patients with NHL and evaluated the correlation between the sIL-2Ralpha levels and clinical characteristics and the International Prognostic Index (IPI). We monitored serum sIL-2Ralpha in 7 patients to compare the changes in their clinical progress with these levels. High levels of serum sIL-2Ralpha (> or =2,000 U/mL) correlated well with parameters defining the high risk group according to the IPI, i.e., high tumor burden at diagnosis (stage III+IV) and lactate dehydrogenase > or =472 U/L. The levels were also associated with B symptoms, bone marrow involvement, and poor response to therapy. The sIL-2Ralpha level decreased during complete remission and was elevated during disease progression or relapse. A high level of sIL-2Ralpha was significantly associated with a low survival rate. These results suggest that serum sIL-2Ralpha might be useful as a biomarker for evaluating the prognosis of patients with NHL at the time of diagnosis and during therapy. A well-controlled, large-scale study is needed to clarify the clinical significance of sIL-2Ralpha in specific groups of NHL.

Clinical significances of serum levels of VEGF and the relationship with IPI in the patients with diffuse large B-cell lymphoma / 白血病·淋巴瘤

Objective To investigate clinical signifieances of serum levels of vascular endothelial growth factor (VEGF) in patients with diffuse large B-cell lymphoma (DLBCL) and to analyze the relationships with international prognostic index (IPI). Methods Serum levels of VEGF were measured by ELISA in 26 cases with newly diagnosed DLBCL and 9 cases with relapsed DLBCL. The clinical data of 26 patients were collected. According to the IPI, 26 patients were divided into two group: low risk group (IPI＜2) and moderate to high risk group (IPI≥2). Results Compared with the normal controls, newly diagnosed and relapsed DLBCL had significantly higher VEGF serum levels (P ＜0.01). In the patients responding to CHOP or RCHOP regimen a significantly decrease in VEGF serum levels occurred, while in the patients who did not achieve complete remission(CR) there was no significant decrease. Furthermore, pretreatment serum levels of VEGF were significantly lower in CR group than in partial remission (PR) and no remission (NR) group. In addition, serum levels of VEGF were significantly elevated in the high risk group than those at the low risk group(P＜0.01). Conclusion The serum levels of angiogenic factor VEGF are related to the development and progression of DLBCL. The VEGF combined with IPI can be used for evaluating the prognosis of DLBCL.

Prognostic significance of international prognostic index(IPI) in peripheral T-cell lymphoma, not otherwise specified / 白血病·淋巴瘤

Objective To evaluate the international prognostic index (IPI) in peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). Methods From May 2005 to May 2008, 75 patients of PTCL--NOS were reviewed. All the patients were diagnosed again by immunohistochemical staining. According to IPI, they were divided into four groups:low risk (0-1), intermediate-low(2), intermediate-high(3), high risk (4-5), then the difference of treatment effectiveness and prognosis among them were analysed. Results IPI scoring of 75 patients were classified as low risk , 10 (13.3%); as intermediate-low, 14 (18.7%); as intermediate-high, 28 (37.3 %); as high risk, 23 (30.7%). There was a significant difference in complete remission rates with first line treatment(X2=16.677,P=0.001), and overall survival rates (P=0.0000) among four groups. Median survival time among 4 groups were 36+, 29.00, 17.00, 10.00 months. 1-year OS were 100.00 %, 89.05 %, 64.24 %, 15.73 %; 2-year OS were: 75.00 %, 53.01%, 34.42 %, 2.00 % respectively. Multivariate analysis showed that both complete remission rates of first line treatment(P=0.002) and IPI(P = 0.049) were independent prognostic factor for PTCL-NOS, while single index of IPI was not. Conclusion At a certain extent, IPI model was able to predict response of treatment effective and prognosis in PTCL-NOS.

Primary Systemic Anaplastic Large Cell Lymphoma in Korean Adults: 11 Years' Experience at Asan Medical Center

PURPOSE: Anaplastic large cell lymphoma (ALCL), a CD30+ T-cell non-Hodgkin's lymphoma, represents only 2-8% of lymphoma overall. Information on the clinical findings of primary systemic ALCL in Korea is limited. Our aims were to report the clinical features and outcomes of primary systemic ALCL. PATIENTS and METHODS: We retrospectively reviewed the medical records of 36 adult patients diagnosed with primary systemic ALCL at Asan Medical Center from February 1995 through June 2006. RESULTS: Of 36 patients, 29 were male. The median age was 39 years (range, 17-67 years), and 26 (72%) presented with Ann Arbor stages III and IV. The most commonly involved extranodal sites were bone (n = 7) and soft tissue (n = 6). Thirty-two of all patients (89%) were treated with an anthracycline-based regimen including cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) as induction chemotherapy; 16 (50%) achieved complete remission (CR), and 13 (41%) achieved partial remission (PR). Median overall survival (OS) and event-free survival (EFS) were 49 and 17 months, respectively. Univariate analysis showed that performance status (p = 0.035), international prognostic index (IPI) (p = 0.025), and age-adjusted IPI (p = 0.034) were significant prognostic factors for OS, whereas anaplastic lymphoma kinase (ALK) expression did not affect OS (p = 0.483). CONCLUSION: Our retrospective analysis of Korean primary systemic ALCL patients showed that median OS was 49 months and overall response to CHOP was 91%. Performance, IPI, and age-adjusted IPI were predictors of OS, whereas ALK expression did not have prognostic significance.

The relationships between the serum levels of β2-MG, VEGF, bFGF, and IL-6 in patients with diffuse large B cell lymphoma and parameters of International Prognostic Index / 肿瘤

Objective: This study aimed to determine the relationships between serum levels of vascular endothelial growth factor (VGEF), interleukin-6 (IL-6), basic fibroblast growth factor (bFGF), β2 -microglobin (β2-MG) and the parameters of International Prognostic Index (IPI) in patients with diffuse large B cell lymphoma (DLBCL). Methods: Thirty three newly diagnosed DLBCL patients were divided into two groups: low risk group (IPI <2) and moderate to high risk group (IPI≥2). Serum levels of VEGF, IL-6, and bFGF were measured by enzyme-linked immunosorbent assay. Radioimmunoassay was applied to detect the serum level of β2-MG. Results: Serum levels of β2-MG, VEGF, bFGF, and IL-6 were significantly elevated in the high risk group than those in the low risk group. Conclusions: The serum levels of β2-MG, VEGF, bFGF, and IL-6 combined with IPI can be used for evaluating the prognosis of DLBCL patients. Detection of these cytokines provides the clue for implementing appropriate therapeutic approaches for individual patients and designing new clinical trails.

Prognostic Factors of Nasal NK/T Cell Lymphoma / 대한이비인후과학회지

BACKGROUND AND OBJECTIVES: Nasal natural killer T (NK/T) cell lymphomas are relatively common in Asia, but the prognostic factors are not well known. The purpose of this research was therefore to evaluate those prognostic factors. SUBJECTS AND METHOD: We reviewed and analyzed the medical records of 68 patients diagnosed as nasal NK/T cell lymphomas between 1984 and 2003 at Ajou University Hospital and at Yonsei University Hospital. Prognostic factors that include age, B symptoms, serum lactate dehydrogenase (LDH) levels, Eastern cooperative oncology group (ECOG) performance status, international prognostic indices (IPI), treatment modality, and Ann Arbor tumor stages were analyzed using the methods of univariate and multivariate statistics. RESULTS: The five-year overall survival rate was 43%. By univariate analysis, we found ECOG performance status, Ann Arbor tumor stages, B symptoms, and IPI to be significant prognostic factors of nasal NK/T cell lymphoma. The multivariate analysis showed that ECOG performance status and B symptoms were significant. CONCLUSION: ECOG performance status, Ann Arbor tumor stages, B symptoms, and IPI could all be prognostic factors of the nasal NK/T cell lymphoma. Among these factors, ECOG performance status and B symptoms may be regarded more useful in diagnosis of the disease than others.

Evolución de los linfomas no Hodgkin de células grandes según el Índice Pronóstico Internacional / Evolution of the large cell non-Hodgkin's lymphomas according to the International Prognostic Index

El Índice Pronóstico Internacional (IPI) agrupa una serie de factores pronósticos que permiten predecir la probable evolución clínica de los linfomas no Hodgkin (LNH). Se empleó en 121 pacientes con diagnóstico de LNH de células grandes, se estratificó en 2 grupos etáreos, y estos a su vez en 4 grupos pronóstico(GP); en el Grupo A donde se agrupó los pacientes de todas las edades, el mayor número se ubicó en los GP Bajo (GPB) y Bajo-Intermedio (GPBI) con 41,32 y 38, 02 %, respectivamente. Se obtuvo el 47, 1 % de Remisión Completa (RC), las mayores se alcanzaron en el GPB (54 %) y en el GPBI (52 %). La probabilidad de Supervivencia Global (SG) a los 5 años fue del 60 %, la mayor se obtuvo en el GPB (75 %) y en el GPBI (62 %). El Grupo B tuvo los pacientes de 60 años o menos, la mayor cantidad se ubicó en los GPBI (43, 6 %) y en el Alto-Intermedio (37, 2 %) , en este grupo se alcanzó el 50 % de RC, la mejor respuesta terapéutica se obtuvo en el GP Alto con el 100 % de RC (pero con sólo 2 pacientes), seguido del GPB con el 69, 2 %. La SG a los 5 años fue del 66 %, la más elevada fue la del GPB (90 %), seguida por el GPBI (65 %). Se demostró que, de forma general, se obtienen resultados superiores, en relación con RC y SG, en el Grupo que analiza sólo a los pacientes menores de 60 años y en los Grupos de pronóstico bueno (GPB y GPBI).

The International Prognostic Index (IPI) groups a series of prognostic factors that allow to predict the probable clinical evolution of non-Hodgkin's lymphomas (NHL). It was used in 121 patients with diagnosis of large-cell NHL. It was stratified into 2 age groups and these at the same time were divided into 4 Prognostic Groups (PG). In the Group A, where pàtients of all ages were included, the greatest number was found in the Low Prognostic Groups (LPG) and Low-Intermediate Prognostic Groups (LIPG) with 41.32 and 38.02 %, respectively. Complete Remission (CR) was attained in 47.1 %. The highest figures of remissions were observed in the LPG (54 %) and in the LIPG (52 %) The probability of Global Survival (GS) at 5 years was 60 %. The highest was obtained in the LPG (75 %) and in the LIPG (62 %). Group B included patients aged 60 or under. Most of them were in the LIPG (43.6 %) and in the High-Intermediate Prognostic Group (37.2 %). 50 % of CR was achieved in this group. The best therapeutic response was obtained in the High PG with 100 % of CR (but with only 2 patients), followed by the LPG with 69.2 %. GS at five years was 66 %. The highest was that of the LPG (90 %), followed by the ILPG (65 %). It was proved in a general way that better results are obtained in relation to CR and GS in the group analizing only patients under 60 and in the groups of good prognosis (LPG and LIPG).